Published • loading... • Updated
FDA Issues Additional Tazverik Blood Cancer Warnings After Market Recall
Summary by aboutlawsuits.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
FDA Issues Additional Tazverik Blood Cancer Warnings After Market Recall
More than 5% of patients developed a secondary form of blood cancer during treatment with Tazverik, which was removed from the market in March. Despite its removal from the market in March, federal regulators are issuing new warnings urging doctors not to give patients the lymphoma drug Tazverik due to a higher-than-expected risk of blood cancers. Tazve…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
